Pu Xiaolin, Wang Jun, Xu Lin, Ma Junqing, Wang Zhilu, Liu Fuyin, Yang Min, Fan Weifei, Meng Lijuan
The Institute of Geriatrics of Jiangsu Province, Nanjing 210024, China.
Zhongguo Fei Ai Za Zhi. 2009 Jan 20;12(1):49-53. doi: 10.3779/j.issn.1009-3419.2009.01.008.
Vinorelbine plus cisplatin/carboplatin (NP) is one of the standard combination chemotherapy regimen for advanced non-small cell lung cancer (NSCLC). The aim of this study is to investigate the relationship between expression of Stathmin and beta-tubulin-III in NSCLC biopsies and sensitivity to Vinorelbine, which would provide a basis of the proper medicine choice for the patients' tailored chemotherapy.
Western blot was used to investigate the expression of Stathmin and beta-tubulin-III protein in the biopsies from stage IIIB-IV NSCLC patients. All the cases were divided into 4 groups according to the level of the two proteins, of which L represented both protein expressed lowly, B showed beta-tubulin-III lowly expressed group, while S showed Stathmin lowly, and H represented both protein highly expressed. At the same time, all the patients accepted NP chemotherapy for 2 or 4 cycles according to the responses to this regimen. The responses rate (RR), media survival time (MST), time to progress (TTP) were observed.
A total of 90 stage IIIB-IV NSCLC patients were divided into 4 groups, 22 in L group, 23 in B and S group while 22 in H group respectively. The RR of the groups were 68.2%, 26.1%, 30.4% and 22.7% respectively. There were statistically significant differences between L group and other 3 groups (P <0.05). The MST were 377, 305, 321 and 271 days respectively, and the TTP were 240, 182, 190 and 166 days in the 4 groups. Statistically significant differences between L group and other 3 groups (P <0.05) can be seen in both MST and TTP.
The expression of beta-tubulin-III and Stathmin in advanced NSCLC biopsies had relationship with the sensitivity to NP chemotherapy regimen in the patients. Cases with high level of these two proteins would have poor responses to this cytotoxic drug.
长春瑞滨联合顺铂/卡铂（NP）是晚期非小细胞肺癌（NSCLC）的标准联合化疗方案之一。本研究旨在探讨NSCLC活检组织中Stathmin和β-微管蛋白III的表达与对长春瑞滨敏感性之间的关系，为患者个体化化疗的合理用药选择提供依据。
采用蛋白质免疫印迹法检测IIIB-IV期NSCLC患者活检组织中Stathmin和β-微管蛋白III蛋白的表达。根据两种蛋白的表达水平将所有病例分为4组，其中L组表示两种蛋白均低表达，B组表示β-微管蛋白III低表达组，S组表示Stathmin低表达组，H组表示两种蛋白均高表达。同时，所有患者根据对该方案的反应接受2或4周期的NP化疗。观察缓解率（RR）、中位生存期（MST）、疾病进展时间（TTP）。
90例IIIB-IV期NSCLC患者分为4组，L组22例，B组和S组各23例，H组22例。各组RR分别为68.2%、26.1%、30.4%和22.7%。L组与其他3组之间差异有统计学意义（P<0.05）。4组的MST分别为377、305、321和271天，TTP分别为240、182、190和166天。L组与其他3组在MST和TTP方面差异均有统计学意义（P<0.05）。
晚期NSCLC活检组织中β-微管蛋白III和Stathmin的表达与患者对NP化疗方案的敏感性有关。这两种蛋白高水平表达的病例对这种细胞毒性药物反应较差。
